{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T12:18:53Z","timestamp":1758457133346,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microvascular Research"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.mvr.2022.104344","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T02:57:06Z","timestamp":1644980226000},"page":"104344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["IL33 and sST2 serum level in systemic sclerosis microvascular involvement"],"prefix":"10.1016","volume":"142","author":[{"given":"Chiara","family":"Pellicano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Iannazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Romaggioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.mvr.2022.104344_bb0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/keq097","article-title":"Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions","volume":"49","author":"Amanzi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.mvr.2022.104344_bb0010","doi-asserted-by":"crossref","first-page":"iv43","DOI":"10.1093\/rheumatology\/kel310","article-title":"Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement?","volume":"45 Suppl 4","author":"Cutolo","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.mvr.2022.104344_bb0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.autrev.2018.01.023","article-title":"Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA to measure peripheral blood perfusion in scleroderma patients","volume":"17","author":"Cutolo","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.mvr.2022.104344_bb0020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.mvr.2022.104344_bb0025","article-title":"Definition and application of proximal-distal gradient finger perfusion in systemic sclerosis by laser speckle contrast analysis","volume":"140","author":"Di Battista","year":"2021","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.mvr.2022.104344_bb0030","article-title":"Relationship between soluble protein ST2 (sST2) levels and microvascular complications in a cohort of patients with type 1 diabetes","author":"Forga","year":"2021","journal-title":"Endocrinol. Diabetes. Nutr. (Engl. Ed.)"},{"issue":"8","key":"10.1016\/j.mvr.2022.104344_bb0035","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/rheumatology\/kes049","article-title":"Evaluation of chronic kidney disease epidemiology collaboration equation to estimate glomerular filtration rate in scleroderma patients","volume":"51","author":"Gigante","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.mvr.2022.104344_bb0040","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/rheumatology\/keaa514","article-title":"Laser speckle contrast analysis predicts major vascular complications and mortality of patients with systemic sclerosis","volume":"60","author":"Gigante","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"344","key":"10.1016\/j.mvr.2022.104344_bb0045","doi-asserted-by":"crossref","first-page":"re8","DOI":"10.1126\/scisignal.2005189","article-title":"Signaling mechanisms of the epithelial-mesenchymal transition","volume":"7","author":"Gonzalez","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.mvr.2022.104344_bb0050","first-page":"1","article-title":"Increased serum levels of soluble ST2 as a predictor of disease progression in systemic sclerosis","volume":"2","author":"G\u00fcnther","year":"2021","journal-title":"Scand. J. Rheumatol."},{"issue":"12","key":"10.1016\/j.mvr.2022.104344_bb0055","first-page":"2423","article-title":"Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study","volume":"34","author":"Hachulla","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.mvr.2022.104344_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cca.2020.04.011","article-title":"Soluble ST2: a complex and diverse role in several diseases","volume":"507","author":"Homsak","year":"2020","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.mvr.2022.104344_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/rheumatology\/kew047","article-title":"Digital ulcers in systemic sclerosis","volume":"56","author":"Hughes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.mvr.2022.104344_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104064","article-title":"Digital ulcers in systemic sclerosis","volume":"50","author":"Hughes","year":"2021","journal-title":"Presse Med."},{"key":"10.1016\/j.mvr.2022.104344_bb0075","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3389\/fimmu.2018.02432","article-title":"IL-33\/ST2 Axis in organ fibrosis","volume":"9","author":"Kotsiou","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.mvr.2022.104344_bb0080","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2353\/ajpath.2008.080014","article-title":"Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation","volume":"173","author":"K\u00fcchler","year":"2008","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.mvr.2022.104344_bb0085","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.mvr.2022.104344_bb0090","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.3389\/fimmu.2018.02663","article-title":"Interleukin-33 in systemic sclerosis: expression and pathogenesis","volume":"9","author":"Li","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mvr.2022.104344_bb0095","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ard.2009.119321","article-title":"The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis","volume":"69","author":"Manetti","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.mvr.2022.104344_bb0100","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1136\/ard.2010.148247","article-title":"Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement","volume":"70","author":"Manetti","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.mvr.2022.104344_bb0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.mvr.2022.104344_bb0110","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing","volume":"26","author":"Medsger","year":"1999","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.mvr.2022.104344_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003331","article-title":"The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u2018alarmin\u2019?","volume":"3","author":"Moussion","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.mvr.2022.104344_bb0120","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.mvr.2011.07.009","article-title":"In systemic sclerosis macrovascular damage of hands digital arteries correlates with microvascular damage","volume":"82","author":"Rosato","year":"2011","journal-title":"Microvasc. Res."},{"issue":"6","key":"10.1016\/j.mvr.2022.104344_bb0125","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.semarthrit.2011.11.005","article-title":"Intrarenal hemodynamic parameters correlate with glomerular filtration rate and digital microvascular damage in patients with systemic sclerosis","volume":"41","author":"Rosato","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.mvr.2022.104344_bb0130","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/acr.22309","article-title":"Increased intrarenal arterial stiffness may predict the occurrence of new digital ulcers in systemic sclerosis","volume":"66","author":"Rosato","year":"2014","journal-title":"Arthritis. Care. Res. (Hoboken)"},{"issue":"5","key":"10.1016\/j.mvr.2022.104344_bb0135","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/art.24394","article-title":"Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients","volume":"61","author":"Sebastiani","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.mvr.2022.104344_bb0140","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/538589","article-title":"Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy","volume":"2010","author":"Shanmugam","year":"2010","journal-title":"Int. J. Rheumatol."},{"issue":"5","key":"10.1016\/j.mvr.2022.104344_bb0145","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3899\/jrheum.151018","article-title":"Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: an open-label study","volume":"43","author":"Smith","year":"2016","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.mvr.2022.104344_bb0150","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/annrheumdis-2012-201553","article-title":"Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis","volume":"72","author":"Terras","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.mvr.2022.104344_bb0155","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3899\/jrheum.081044","article-title":"Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (Itin\u00e9rAIR-Scl\u00e9rodermie)","volume":"36","author":"Tiev","year":"2009","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.mvr.2022.104344_bb0160","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/medicina55020050","article-title":"IL33\/ST2 Axis in diabetic kidney disease: a literature review","volume":"55","author":"Tonacci","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.mvr.2022.104344_bb0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.mvr.2022.104344_bb0170","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"Van den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.mvr.2022.104344_bb0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/sji.12317","article-title":"Increased serum levels of the IL-33 neutralizing sST2 in limited cutaneous systemic sclerosis","volume":"82","author":"Wagner","year":"2015","journal-title":"Scand. J. Immunol."},{"issue":"37 Suppl 119","key":"10.1016\/j.mvr.2022.104344_bb0180","first-page":"141","article-title":"Role of IL-33\/ST2 signaling pathway in systemic sclerosis and other fibrotic diseases","volume":"4","author":"Xu","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.mvr.2022.104344_bb0185","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10067-011-1686-5","article-title":"Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis","volume":"30","author":"Yanaba","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.mvr.2022.104344_bb0190","doi-asserted-by":"crossref","first-page":"6540937","DOI":"10.1155\/2016\/6540937","article-title":"Serum levels of soluble ST2 and IL-10 are associated with disease severity in patients with IgA nephropathy","volume":"2016","author":"Zhang","year":"2016","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.mvr.2022.104344_bb0195","first-page":"2778","article-title":"Increased soluble ST2 and IL4 serum levels are associated with disease severity in patients with membranous nephropathy","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Med. Rep."}],"container-title":["Microvascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286222000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286222000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T05:58:47Z","timestamp":1758434327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026286222000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":39,"alternative-id":["S0026286222000346"],"URL":"https:\/\/doi.org\/10.1016\/j.mvr.2022.104344","relation":{},"ISSN":["0026-2862"],"issn-type":[{"type":"print","value":"0026-2862"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL33 and sST2 serum level in systemic sclerosis microvascular involvement","name":"articletitle","label":"Article Title"},{"value":"Microvascular Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mvr.2022.104344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104344"}}